XML 70 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation Expense (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-Based Compensation Expense
Compensation expense related to stock-based awards was recorded as follows:
Years Ended December 31,
(in millions)202420232022
Cost of revenue$0.7 $0.4 $0.4 
Research and development9.0 11.5 8.9 
Selling, general and administrative59.6 36.4 31.6 
Total$69.3 $48.3 $40.9 
Schedule of Stock Option Activity
The following summarizes the activity under the Company’s stock option plans:
Number of
Options
Weighted Average
Exercise Price
Weighted Average Remaining Contractual Term
(in years)
Aggregate
Intrinsic
Value
(in millions)
Outstanding at December 31, 2023
436,094 $135.37 
Granted138,108 $166.62 
Exercised(127,125)$64.24 $16.5 
Forfeited and canceled(47,682)$246.17 
Outstanding at December 31, 2024
399,395 $155.65 6$43.4 
Vested, December 31, 2024
202,279 $113.10 3.3$30.5 
Vested or expected to vest, December 31, 2024
370,691 $153.06 5.7$41.2 
Schedule of Assumptions Used for Options Granted
The assumptions used in the Black-Scholes pricing model for options granted during each year, along with the weighted-average grant-date fair values, were as follows:
 Years Ended December 31,
 202420232022
Risk-free interest rate
4.4%
4.3%
1.8%
Expected life of options (in years)
4.1
4.2
4.2
Dividend yield—%—%—%
Expected stock price volatility
46.2%
45.7%
42.8%
Fair value per option$69.48$115.32$93.26
Schedule of Restricted Stock Units
Activity for RSUs is as follows:
Number of
Shares
Weighted
Average
Fair Value
Outstanding at December 31, 2023
249,194 $255.31 
Granted279,528 $171.23 
Vested(108,839)$260.01 
Forfeited(27,137)$215.48 
Outstanding at December 31, 2024
392,746 $196.74 
Schedule of Performance Stock Units
Activity for PSUs is as follows:
Number of
Shares
Weighted
Average
Fair Value
Outstanding at December 31, 2023
122,466 $261.65 
Granted(1)
137,383 $166.86 
Vested(16,677)$278.97 
Forfeited(6,400)$261.63 
Outstanding at December 31, 2024(2)
236,772 $205.74 
(1) Includes a 675 share adjustment to awards granted in 2021 for the three-year performance cycle award period ended 2023, based on the actual performance achievement of 111%.
(2) Based on 169% achievement of the performance metrics, approximately 83,000 shares of Insulet were earned for awards that were granted in 2022 for the performance period ended December 31, 2024. These shares vest in February 2025.
Schedule of Estimated Fair Value of Share Purchase Under ESPP
The estimated fair value of shares purchased under the ESPP were based on the following assumptions:
 Years Ended December 31,
 202420232022
Risk-free interest rate
 4.4% - 5.4%
5.3% - 5.4%
1.6% - 4.7%
Expected term (in years)0.50.50.5
Dividend yield—%—%—%
Expected stock price volatility
34.2% - 40.9%
29.1% - 47.0%
44.3% - 50.1%